» Articles » PMID: 34422664

A Pipeline for Predicting the Treatment Response of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Using Single MRI Modality: Combining Deep Segmentation Network and Radiomics Analysis Based on "Suspicious Region"

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Aug 23
PMID 34422664
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with locally advanced rectal cancer (LARC) who achieve a pathologic complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) typically have a good prognosis. An early and accurate prediction of the treatment response, i.e., whether a patient achieves pCR, could significantly help doctors make tailored plans for LARC patients. This study proposes a pipeline of pCR prediction using a combination of deep learning and radiomics analysis. Taking into consideration missing pre-nCRT magnetic resonance imaging (MRI), as well as aiming to improve the efficiency for clinical application, the pipeline only included a post-nCRT T2-weighted (T2-w) MRI. Unlike other studies that attempted to carefully find the region of interest (ROI) using a pre-nCRT MRI as a reference, we placed the ROI on a "suspicious region", which is a continuous area that has a high possibility to contain a tumor or fibrosis as assessed by radiologists. A deep segmentation network, termed the two-stage rectum-aware U-Net (tsraU-Net), is designed to segment the ROI to substitute for a time-consuming manual delineation. This is followed by a radiomics analysis model based on the ROI to extract the hidden information and predict the pCR status. The data from a total of 275 patients were collected from two hospitals and partitioned into four datasets: Seg-T (N = 88) for training the tsraUNet, Rad-T (N = 107) for building the radiomics model, In-V (N = 46) for internal validation, and Ex-V (N = 34) for external validation. The proposed method achieved an area under the curve (AUC) of 0.829 (95% confidence interval [CI]: 0.821, 0.837) on In-V and 0.815 (95% CI, 0.801, 0.830) on Ex-V. The performance of the method was considerable and stable in two validation sets, indicating that the well-designed pipeline has the potential to be used in real clinical procedures.

Citing Articles

Deep learning algorithms for predicting pathological complete response in MRI of rectal cancer patients undergoing neoadjuvant chemoradiotherapy: a systematic review.

Jong B, Yu Z, Hsu Y, Chiang S, You J, Chern Y Int J Colorectal Dis. 2025; 40(1):19.

PMID: 39833443 PMC: 11753312. DOI: 10.1007/s00384-025-04809-w.


The Role of Predictive and Prognostic MRI-Based Biomarkers in the Era of Total Neoadjuvant Treatment in Rectal Cancer.

Curcean S, Curcean A, Martin D, Fekete Z, Irimie A, Muntean A Cancers (Basel). 2024; 16(17).

PMID: 39272969 PMC: 11394290. DOI: 10.3390/cancers16173111.


Recent trends in AI applications for pelvic MRI: a comprehensive review.

Tsuboyama T, Yanagawa M, Fujioka T, Fujita S, Ueda D, Ito R Radiol Med. 2024; 129(9):1275-1287.

PMID: 39096356 DOI: 10.1007/s11547-024-01861-4.


Image-based artificial intelligence for the prediction of pathological complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer: a systematic review and meta-analysis.

Shen H, Jin Z, Chen Q, Zhang L, You J, Zhang S Radiol Med. 2024; 129(4):598-614.

PMID: 38512622 DOI: 10.1007/s11547-024-01796-w.


Fully semantic segmentation for rectal cancer based on post-nCRT MRl modality and deep learning framework.

Xia S, Li Q, Zhu H, Zhang X, Shi Y, Yang D BMC Cancer. 2024; 24(1):315.

PMID: 38454349 PMC: 10919051. DOI: 10.1186/s12885-024-11997-1.


References
1.
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

2.
Benson A, Venook A, Al-Hawary M, Cederquist L, Chen Y, Ciombor K . Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018; 16(7):874-901. PMC: 10203817. DOI: 10.6004/jnccn.2018.0061. View

3.
Liu Z, Zhang X, Shi Y, Wang L, Zhu H, Tang Z . Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Clin Cancer Res. 2017; 23(23):7253-7262. DOI: 10.1158/1078-0432.CCR-17-1038. View

4.
Yang F, Ford J, Dogan N, Padgett K, Breto A, Abramowitz M . Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. Transl Androl Urol. 2018; 7(3):445-458. PMC: 6043736. DOI: 10.21037/tau.2018.06.05. View

5.
Jia H, Shen X, Guan Y, Xu M, Tu J, Mo M . Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer. Radiother Oncol. 2018; 128(3):548-556. DOI: 10.1016/j.radonc.2018.06.022. View